cyrilzakka/clinical-trials huggingface dataset:
The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults.

This study investigates the concentration levels of NAD+/NADH in peripheral blood samples and immune cells of healthy adults of different age groups under daily physiological and lifestyle conditions, in order to determine the baseline levels of NAD+/NADH in adult populations of different age groups and genders. Simultaneously examining the biological status and function of human immune cells, blood biochemistry, biological age levels, to explore the biological function and mechanism of NAD+/NADH in the aging process of the human body.

In this study, 60 subjects will be enrolled in three groups according to the age range of 20-40, 41-60 and 61-80. Each group has 20 subjects, and the sex ratio of each group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups. At the same time, the subjects tested Hematology, blood biochemical indicators, as well as the expression of subsets of peripheral blood immune cells and SIRT1 level at the same time point, to study the change trend of NAD+/NADH level in different age groups, and the correlation between this trend and Hematology age, immune indicators.

Eligibility Criteria:
Inclusion Criteria:

* 1. Male/females of 18 to 85 years of age.

  2. Able to provide written Informed Consent.

  3. Body Mass Index ranging from 18 to 25 kg/m2(bounds included), with a stable weight over the last 2 months (±2.5 kg).

  4. Able to follow verbal and written study directions.

  5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.

  6.Able to maintain consistent diet and lifestyle habits according to the study

Exclusion Criteria:

* 1. Male/females of 18 to 85 years of age.

  2. Able to provide written Informed Consent.

  3. Body Mass Index ranging from 18 to 25 kg/m2(bounds included), with a stable weight over the last 2 months (±2.5 kg).

  4. Able to follow verbal and written study directions.

  5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.

  6. Able to maintain consistent diet and lifestyle habits according to the study.
Self-sampling for Non-attenders to Cervical Cancer Screening

The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.

Despite the existence of an effective cervical cancer screening in the Czech Republic, cervical cancer is the cause of about 800 new cases and 400 deaths every year. One of the major problem of the Czech cervical cancer screening is low participation. An effective strategy to increase cervical cancer screening attendance is one of the main challenges. The offering of self-sampling to the cervical cancer screening non-attenders could increase women's participation as was shown in several European countries.

The trial should determine acceptability of the self-sampling followed by HPV DNA test by Czech women and therefore usability of the self-sampling device to increase cervical cancer screening attendance among under-screened women. Three different approaches will be tested: women will receive a self-sampling device by mail (Arm A); receive a self-sampling device by gynecologist (Arm B); receive a self-sampling device by general practitioner (Arm C). Comparisons of the screening attendance among the arms will be made. To address also potential effects on inequities, the analyses will include comparisons by sociodemographic characteristics. Women from the database of commercial vendor will be included to the Arm A regardless of whether or not they participate in cervical cancer screening program. Women who do not participate in cytology-based cervical cancer screening program for at least three years will be included through their gynecologist (Arm B) or general practitioner (Arm C) database.

The second focus of the trial is the evaluation of high-risk human papillomavirus prevalence in screening population of Czech women (attenders and non-attenders of cervical cancer screening) since there are no relevant data for the Czech Republic. Study participants may volunteer for archiving of remaining biological materials for future studies.

Eligibility Criteria:
Inclusion Criteria:

* Women with age 30-65 years; for arm A women \> 65 years are allowed
* Women live in the Czech Republic.
* Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).
* Women with completed informed consent.
* Women capable of self-sampling of cervicovaginal swab.

Exclusion Criteria:

* Pregnant women.
* Women with no sexual intercourse experience.
* Women after hysterectomy including cervix.
Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.

The purpose of this study is to evaluate the clinical efficacy and safety of Cnidium Monnieri Detoxification Formula in clearing HPV infection, improving clinical symptoms and quality of life in female patients with persistent cervical high-risk HPV infection.

Persistent infection with high-risk HPV is a major cause of cervical cancer and has negative psychosocial effects on women's health-related quality of life (QOL). This prospective, single-arm, multicenter study is to evaluate the clinical efficacy and safety of Cnidium Monnieri Detoxification Formula in clearing HPV infection, improving clinical symptoms and quality of life in female patients with persistent cervical high-risk HPV infection.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 25 years to ≤ 75 years，with sexual life history
* Meet the diagnostic criteria for high-risk human papillomavirus (HR-HPV) persistent infection
* After surgery or physical therapy for high-grade squamous intraepithelial lesions (HSIL) of the cervix or high-grade squamous intraepithelial lesions (VaINIII) of the vagina, or radical surgery for cervical/vaginal cancer or radical chemoradiotherapy, the examination remained positive for HR-HPV ≥6 months after the end of treatment, with the same type or multiple types as before treatment, and no progression or recurrence of the disease.
* No local or systemic therapy has been administered to patients in the last 3 months
* Patients were informed of the study protocol, agreed to cooperate with the treatment, and signed informed consent.

Exclusion Criteria:

* Only low-risk HPV infection
* Colposcopy for high-grade intraepithelial lesions or cancer of the cervix, vagina, vulva, who have not received or are receiving treatment
* Immunocompromised or immunosuppressant
* Pregnant and lactating women
* Patients with other malignant tumors not controlled, serious heart, lung, liver, renal insufficiency and coagulation dysfunction
* People with communication or cognitive impairment
* Patients have contraindications to oral administration of traditional Chinese medicine preparations
* In the same period, other anti-HPV measures were used to treat, which affected the efficacy judgment
Modified Atkins Diet Plus KetoCal for Adult Epilepsy

The modified Atkins diet (MAD) has been shown to be effective in treating children and adults with medically resistant seizures. A recent study in children showed that the use of KetoCal® once per day in addition to the MAD appeared to be beneficial when used during the first month. The investigators hypothesize that including a daily KetoCal® liquid tetrapak with one meal during the initial month of the MAD will produce urinary ketosis in more adult patients than the MAD alone and will lead to greater seizure reduction.


Eligibility Criteria:
Inclusion Criteria:

* Adults ages \>17 years.
* At least weekly seizures (or 4 per month). All seizure types allowed.
* Tried at least two anticonvulsants.

Exclusion Criteria:

* Unwilling to restrict carbohydrates
* Significantly underweight (Body Mass Index \<18.5)
* Prior use of the modified Atkins diet for ≥ 2 days
* Prior use of KetoCal® at any time for any duration
* Use of the ketogenic diet within the past year
* Kidney disease
* History of hypercholesterolemia (total cholesterol \> 300 mg/dl) or hypertriglyceridemia (triglycerides \> 200 mg/dl)
* Metabolic or mitochondrial disorder
* Pregnancy or breastfeeding
* Lactose intolerance or milk allergy
* Aversion to liquids or inability to eat solid food
Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS)

This is a prospective randomized controlled trial investigating the effect of vibration therapy on bone mineral density (BMD) and bone quality in AIS subjects suffering from osteopenia (low bone mass).

Scoliosis is a three-dimensional spinal deformity and AIS is the commonest with a high prevalence of 2-4 % in the general population. As many as 30% of AIS subjects also suffer from osteopenia which can persist and result in serious health problems later in life including vertebral collapse, fragility fractures, decreased quality of life and even mortality. In spite of this, a safe, effective and evidence-based treatment protocol for AIS-related osteopenia is not available. It remains uncertain how effective dietary advices, physical activity, Calcium and Vitamin D supplements are in this regard. On the other hand, low-magnitude high-frequency vibration therapy was shown to be effective in increasing bone mass both in animal models and in clinical trials involving elderly subjects. AIS-related osteopenia may have a different clinical behaviour. In addition, the in-vivo effect on bone quality has never been studied. We plan to carry out a scientific clinical study on the effect of vibration therapy on skeletally mature female AIS subjects with osteopenia. They are randomly allocated to either the treatment or the control group. BMD, bone micro-architectures are assessed to delineate whether vibration therapy has any therapeutic effect on improving low bone mass in osteopenic AIS subjects.

Eligibility Criteria:
Inclusion Criteria:

* 15 to 25 year-old female patients suffering from clinically and radiologically diagnosed AIS
* more than 18 months post-menarche and Risser's sign equal to or greater than 4, and fusion of epiphyseal plate of all phalanges and metacarpals of the left hand and wrist.
* The Cobb's angle of the major structural curve is between 10 to 50 degrees (inclusive)
* Z-score BMD of less than -1

Exclusion Criteria:

* medical or musculoskeletal conditions that contraindicate or prevent the patients from receiving vibration therapy
* subjects who are not willing to comply with the treatment protocol
* subjects suffering from any medical conditions that affect bone metabolism such as hyperparathyroidism, hyperthyroidism, osteomalacia, acute or chronic renal or liver disease
* treatment with medication that affects bone metabolism such as bisphosphonate, steroid.
* pregnancy
* history of spinal operation done for scoliosis
* smokers or drinkers
Exercise Training in Depressed Traumatic Brain Injury Survivors

The purpose of this study is to determine the feasibility of successfully delivering moderate intensity aerobic exercise training to depressed traumatic brain injury subjects between one and three years after injury.

Traumatic brain injury (TBI) alters the lives of many civilians and those involved in armed conflicts. Sequelae of TBI includes depression in up to 30% of cases. Appearance of depression after TBI impairs recovery and results in sub-optimal re-integration into society. Treatment of post TBI depression relies on oral medications, whose efficacy and side effect profile is sub-optimal. Exercise training is effective in spontaneous depression as a stand alone treatment and in conjunction with oral medications, and this may represent an alternative treatment option in the TBI population. Further, the pathophysiology of depression after TBI has yet to be examined with the full scientific rigor required. This project proposes to use exercise training of moderate intensity as a treatment for depression after TBI, while measuring biological markers as a way to investigate efficacy and provide insight into the pathophysiology.

Eligibility Criteria:
Inclusion Criteria:

* CT brain with subdural hematoma, subarachnoid hemorrhage, and/or cortical contusion
* Glasgow outcome scale extended of 4 to 8
* speaks English
* Beck Depression Inventory -II score between 14 and 28
* sedentary life style
* one to three years after traumatic brain injury

Exclusion Criteria:

* prior history of brain process (example, stroke, brain tumor)
* aphasia
* psychosis, mania, bipolar disorder, schizophrenia
* pregnancy
* inability to exercise via cycles or treadmill
Effects of Foam Rolling, Foam Rolling with Dynamic Movement, and Static Stretching on Plantar Flexor Range of Motion and Tissue Properties in Healthy Participants

Each voluntary participant will be invited and tested at the Functional Assessment Laboratory. After reading and completing the informed consent document regarding our research and data processing, participants will be invited for four separate sessions at the laboratory. During the first session, essential personal information (name, surname, sex, age) will be recorded. Immediately after measuring the participant's height using a stadiometer and weight using a scale, several tests will be conducted to assess pain thresholds and tissue density using specific dynamometers, joint mobility levels of the participants (Passive Muscle Mobility Test and a test using the accelerometer), and a Bioimpedance Analysis to assess body fluids. After a 15-minute rest period, the tests will be repeated to obtain an initial baseline control assessment. The subsequent sessions will involve the same evaluations, which will be conducted before, immediately after, and 15 minutes after the proposed intervention. The proposed interventions will be randomized across the sessions and will alternatively include: a brief session of static stretching on the leg muscles (4 sets of 30 seconds with 15 seconds of rest between sets), a session of static foam rolling (4 sets of 30 seconds with 15 seconds of rest between sets) on the same muscle groups, where pressure is applied to the muscle through the participant's body weight on a foam roller while performing muscle contractions, or dynamic foam rolling, during which the muscle will be rolled over the foam roller.


Eligibility Criteria:
Inclusion Criteria:

Healthy participants, adult participants, active, agreeing to sign the consent form

Exclusion Criteria:

Participants with neuromuscular, orthopedic and gynecological disease (or taking oral contraceptives) or those having injuries of the lower extremities were excluded from the investigation. Female participants were allowed to participate to the experiments only during the follicular phase of their menstrual cycle and always before ovulation
A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

1. 18-80 years of age
2. Recurrent cancer diagnosis after at least 5 years in remission or newly diagnosed with any cancer with a solid tumor or non-Hodgkin's Lymphoma and scheduled to undergo at least three rounds of chemotherapy for curative or palliative intent
3. Chemotherapy is given at a minimum of every 3 weeks
4. At least 30 days past radiation therapy
5. Nonpregnant and use of method of contraception per the treating clinician standard of care
6. Life expectancy \> 3 months
7. Stable on all herbal or complementary therapeutics for the past 30 days and agree to not include new complementary therapeutics until after study completion
8. Baseline ECOG ≤ 2
9. In the opinion of the investigator, the subject will be compliant and have a high probability of completing the study including all scheduled evaluations and required tests

Exclusion Criteria:

1. Any hormone receptor positive cancer
2. Abnormal ALT/AST: \> 2.5 to 3 times normal range
3. eGFR \<60
4. Platelets \< 75,000
5. Hb \<8.0
6. ANC \<1000
7. Documentation of a bone marrow transplant
8. Documentation of brain metastases, diagnosis with other cancer, except skin cancer history with basal cell carcinoma, squamous carcinoma
9. Documentation of current seizure disorder
10. Documentation of new cardiac arrhythmias and myocardial infarction
11. Standard of care does not include granulocyte-colony stimulating factor (GCSF) or Neulasta
12. Any active bacterial or viral infection, pneumonia, sepsis, active gastric ulcer, gastritis, nonhealing wound, intractable nausea or vomiting, diarrhea, bleeding disorder
13. Hyperthyroidism, connective tissue disease including systemic lupus erythematous, rheumatoid arthritis
14. Documentation of a current drug abuse disorder
15. Current participation in other clinical trial
Haemodynamic Monitoring in Head and Neck Cancer Patients

In order to estimate the effect of fluid management in regard to postoperative complications this observatory study will document every kind of fluid intervention peri- and intraoperatively.

The extend of mass transfusions is known to correlate with postoperative complications. However, also crystalloid and colloidal infusions are under suspicion to cause postoperative complications. This study will capture any kind of fluid intervention perioperatively as well as intraoperatively. Intraoperative fluid management will be documented and matched with the operation steps respectively. The extend of fluid therapy will be correlated with general postoperative complications and especially with the survival of microvascular transplants.

For this purpose, there will be four questionaires. After informed consent, the first questionaire will cover the patient's history, risk factors and previous operations. The second questionaire will cover intraoperative fluid management, documented with the actual operation step. Furthermore, it will also intraoperative complications, cardiovascular-active medication. For closer monitoring, data from Picco will also be included. The third questionaire will be complete in the ICU covering similar content as the second questionaire. The last questionaire will cover the patient's progress on the general ward. Fluid management and tube feeding, as well as general postoperative complication and flap specific complications will be noted.

This study aims for 50-80 patients.

Eligibility Criteria:
Inclusion Criteria:

* 18 years old or older
* admitted for head and neck surgery with microvascular transplantation due to head and neck tumors

Exclusion Criteria:

* Pregnancy
* underage
* missing informed consent
* revisions and relapse operations
* non tumor-associated operations
* surgery without microvascular transplants
Effect of Oral Lactate Ingestion on Appetite Regulation

The goal if this study is to determine how oral lactate ingestion affects markers of appetite regulation. Researchers will compare oral lactate ingestion to a sodium chloride placebo. Participants will consume the lactate or placebo solution and then have blood samples and assessments of appetite over the course of 90 min. Free-living energy intake will be measured for 3 days surrounding each experimental session.

The purpose of this study is to explore the effects of oral lactate ingestion on appetite regulation in humans. To do this males and females will report to the laboratory for 2 experimental sessions completed in a counterbalanced, double-blinded manner. During one session a lactate solution will be ingested, in another session an equimolar sodium chloride solution will be ingested that matches the osmolarity of the lactate condition. Venous blood samples and subjective appetite perceptions will be obtained at five time points during each experimental session. Energy expenditure will be measured through accelerometers placed on the participants anterior thigh by an investigator on the morning the day before the session and worn over the experimental period (day before, day of, day after) recording their physical activity. Energy intake will be tracked using a smartphone mobile application called Keenoa over the same time period the accelerometers are worn.

Eligibility Criteria:
Inclusion Criteria:

* Deemed healthy using Canadian Society for Exercise Physiology Get Active Questionnaire
* Female participants must be eumenorrheic (menstrual cycle length between 21-35 days)

Exclusion Criteria:

* Failure to meet inclusion criteria
* Taking supplements or medications known to affect metabolism (e.g., creatine, beta-blockers)
* Currently pregnant or a pregnancy of \>3 months within the last 3 years,
Safety and Pharmacology Study of BMS-866949

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable


Eligibility Criteria:
Inclusion Criteria:

* Panels 1-6: Healthy Male Subjects
* Panel 7: Females
* Ages 21 to 55, inclusive
* Body Mass Index (BMI) of 18 to 32 kg/m², inclusive
* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion Criteria:

* History of glaucoma or a confirmed intraocular pressure indicative of glaucoma at screening. (Normal IOP \<21 mmHg)
* History or family history of psychiatric disorder
* Current treatment with prescription medication
* Exposure to any investigational drug or placebo within 12 weeks of study drug administration